Make Biotech Showcase your homebase during the busiest week in healthcare. The event convenes 3,200 life science leaders, including 1,200+ investors and over 340 presenting companies, for three days of breakthrough innovation, investment opportunities and strategic collaborations.
A panel at Biotech Showcase last week provided an outlook for a new class of drugs that only entered the market two years ago, but was decades in the making.
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Efficacy, safety and reimbursement are all important things for CAR-T makers to figure out, but manufacturing is no less important.
Performance- and time-based payment models - like the one bluebird bio has proposed for LentiGlobin - are especially harder to put into practice in the US than in Europe, some executives said at this week's JPM conference.
Hospitals - especially in Europe - anticipate growing interest from international patients. But a wave of industry consolidation is debatable.
The startups highlighted stood out from the pack of some 300 life sciences companies presenting at this week's Biotech Showcase.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.